Replies to post #220122 on Biotech Values

[DewDiligence]

Mavyret’s US new-patient share=51.5%—the highest-ever weekly figure—in the week ending 8/3/18, as reported by IMS. GILD’s US new-patient share was 47.4%, and MRK’s was 1.1%.

Mavyret’s US total-script share reached 45.6% in the week ending 8/3/18, also the highest-ever weekly figure, as reported by IMS. GILD’s US total-script share was 52.8%, and MRK’s was 1.6%.